Mundiphar­ma picks up a PhI­II-ready chemo cre­ation in $250M deal

A small, vir­tu­al Ger­man biotech called Cel­lAct Phar­ma has struck a li­cens­ing deal for their sole clin­i­cal-stage can­cer ther­a­py. The part­ners are stay­ing mum about the de­tails, but it in­cludes a pack­age of mile­stones and a “dou­ble-dig­it” up­front that to­tal $250 mil­lion.

The Dort­mund, Ger­many-based Cel­lAct turned up at AS­CO last sum­mer with col­lec­tive Phase I and II da­ta on 39 pa­tients, which they say demon­strat­ed an abil­i­ty to rein in tu­mor growth among pa­tients with drug-re­sis­tant bil­iary tract can­cer.  The ther­a­py, CAP7.1, is a pro­drug which con­verts in­to the chemother­a­py etopo­side in tar­get tis­sues, pos­si­bly of­fer­ing an al­ter­na­tive ap­proach to treat­ing end-stage dis­ease from sol­id tu­mors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.